Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
Key result
Among obese VTE patients, apixaban was associated with a significantly lower risk of recurrent VTE (HR 0.73; 95% CI 0.64-0.84) and major bleeding compared with warfarin.
Why the study?
The study evaluated the risk of recurrent VTE and major bleeding with apixaban versus warfarin in patients with VTE, stratified by obesity status.
Does apixaban reduce recurrent VTE and major bleeding in obese and morbidly obese patients with VTE compared to warfarin?
Population
112,024 non-obese and 43,095 obese patients with VTE
Comparison
Apixaban vs warfarin
Design
Retrospective observational cohort study using 5 US healthcare claims databases with IPTW
Authors
Discussion
Loading...
Member takes
Implication
May support apixaban preference in obese VTE; extends observational data but leaves randomized confirmation open.
Study Design
Type
Cohort (n=155,119)
Multicenter
Yes
Structured PICO
Does apixaban reduce recurrent VTE and major bleeding in obese and morbidly obese patients with VTE compared to warfarin?
P
Population
155,119 VTE patients (including 43,095 obese and 19,751 morbidly obese) initiating apixaban or warfarin, identified from 5 US healthcare claims databases.
E
Exposure
Apixaban
C
Comparator
Warfarin
O
Outcome
Recurrent venous thromboembolism (VTE) and major bleeding (MB)hard clinical
Main Result
Hazard Ratio: 0.73 (95% CI 0.64–0.84)
In a large US claims database study, apixaban was associated with lower risks of both recurrent VTE and major bleeding compared to warfarin in obese and morbidly obese patients.
Cite This Study
Cohen et al. (2021) conducted a cohort in Venous thromboembolism (VTE) with obesity (n=155,119). Apixaban vs. Warfarin was evaluated on Recurrent VTE (HR 0.73, 95% CI 0.64-0.84). Among obese VTE patients, apixaban was associated with a significantly lower risk of recurrent VTE (HR 0.73; 95% CI 0.64-0.84) and major bleeding compared with warfarin.